In line with previous studies (Biton etal., 2014; Choi etal., 2014), PPARγ was found to be the most active TF in the luminal bladder cancer TCGA subgroup I. Association with genomic alteration suggesting PPARγ to be a major driver of these tumors (see Supplementary Information), which has been recently validated experimentally (Biton etal., 2014). Here, PPARG is linked to urinary bladder cancer.